SPLASH BEVERAGE GROUP ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO CANNEPIL®, AN EPILEPSY THERAPY WITH ESTABLISHED EUROPEAN PATIENT ACCESS, FDA ENGAGEMENT AND U.S. DEVELOPMENT POTENTIAL
FORT LAUDERDALE, Fla., July 7, 2026 /PRNewswire/ -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT) (LSE: RGT) for CannEpil®, a proprietary, patent protected...
FORT LAUDERDALE, Fla., July 7, 2026 /PRNewswire/ -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT) (LSE: RGT) for CannEpil®, a proprietary, patent protected...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.